Source comparison
GHRP-6 Acetate vs Tesamorelin: Research Application Comparison
Visceral fat reduction Minimal direct lipolysis; ghrelin activation may increase appetite and negate fat loss Demonstrated 15.2% VAT reduction in clinical trials; selective GHRH action preserves lipolytic signaling Tesamorelin Tesamorelin's GHRH-specific mecha
This comparison does not assign a generated winner or score.
- Visceral fat reduction
- Minimal direct lipolysis; ghrelin activation may increase appetite and negate fat loss
- Demonstrated 15.2% VAT reduction in clinical trials; selective GHRH action preserves lipolytic signaling
- Tesamorelin
- Tesamorelin's GHRH-specific mechanism directly supports fat oxidation without appetite interference
- Lean mass accretion in aging models
- Broad GH stimulation supports muscle protein synthesis but cortisol co-elevation may impair recovery
- Pulsatile GH release mimics youthful secretion patterns; preserves IGF-1 elevation without cortisol spike
- Natural pulsatility makes tesamorelin more effective for long-term anabolic studies
- Appetite and feeding behavior research
- Ghrelin receptor agonism reliably increases food intake 30–50% in rodent models
- No effect on ghrelin pathways; appetite remains unchanged
- GHRP-6 Acetate
- GHRP-6 is the clear choice when appetite modulation is the endpoint
- Neuroprotection and cognitive function
- GHS-R1a receptors in hippocampus may support neurogenesis; limited clinical evidence
- No direct CNS receptor activity; effects are GH-mediated only
- GHRP-6's hippocampal receptor binding offers unique neuroprotective potential
- Short-term GH challenge tests
- Rapid, predictable GH surge within 30 minutes; easy to time sample collection
- Slower onset (45–60 min); pulsatile release complicates single-timepoint assays
- For acute GH provocation testing, GHRP-6 provides cleaner pharmacokinetics
- Multi-week metabolic studies
- Requires 2–3 daily doses; higher handling burden and contamination risk
- Once-daily dosing improves compliance; lower protocol failure rate
- Simplified dosing makes tesamorelin more reliable in studies lasting 8+ weeks
- Tesamorelin consistently outperforms GHRP-6 acetate in studies where the endpoint is GH-mediated metabolic change. Fat loss, lean mass preservation, IGF-1 elevation. Without confounding appetite or stress hormone effects. GHRP-6 acetate remains the better tool when ghrelin pathway activation itself is the research target, or when rapid, predictable GH spikes are required for acute testing. The 'better' peptide is always context-dependent.